Figure 2.
![Figure 2. Patient cohort survival outcomes. (A) Two-year OS was 55%, and there was no significant difference in OS based upon disease type (AML, MDS, or CML). (B) There was a statistically significant (P = .0010) difference in OS based upon disease status at time of SCT (25% vs 65%, not in CR/CP vs CR/CP). (C-D) There were no significant differences in OS based upon conditioning type (myeloablative conditioning [MAC] or RIC) or donor source (MRD or MUD).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/2/16/10.1182_bloodadvances.2018022475/3/advances022475f2.jpeg?Expires=1724952144&Signature=ZEMLwdChn7SMuhPT3qC9zz47l7XZFzs2X4m7UAPIDpvLnvej52PDtZB-lZq7C6UmsPwGiPwQ6L76eCa5wqndBZ9707~hlxZrEnKBbjUVR6wi-cE69sV2JbIQ02vkV1RBvLGSampyqKk0cJyJunh3aPfnNpL8kvX~Fm~khmTz4638oLJWr8LOqfZVc4oKIAuriHeIF64lGIP6QlTO8Fe2i6-tDTlTGUeGRWS5QZUarblEVkwxcA~Qxhqfa6aczNi99ynXs5akViJ3y75AfyL9XVqp7kMBrc~hrnD-CAvCFtuGAwlp8izDa~bZPkfNvdu8j0c2eozE0V~MChfZ3J8JlA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Patient cohort survival outcomes. (A) Two-year OS was 55%, and there was no significant difference in OS based upon disease type (AML, MDS, or CML). (B) There was a statistically significant (P = .0010) difference in OS based upon disease status at time of SCT (25% vs 65%, not in CR/CP vs CR/CP). (C-D) There were no significant differences in OS based upon conditioning type (myeloablative conditioning [MAC] or RIC) or donor source (MRD or MUD).
